Can the use of semaglutide help in the fight against cardiovascular disease? The latest study suggests that there may indeed be a link. It included tens of thousands of patients with diagnosed heart disease and compared hospitalization rates between those treated with semaglutide and patients receiving standard therapy. In the analyzed population, individuals using semaglutide were admitted to hospital less frequently, both for cardiovascular reasons and for causes not directly related to the heart.
The study authors note that a reduction in hospitalizations may have important clinical and systemic implications, as patients with heart disease belong to groups at particularly high risk of recurrent events and costly inpatient care. However, the analysis was purely observational, meaning it cannot definitively establish a cause-and-effect relationship.
The benefits remained visible even after accounting for differences in age, sex, and coexisting conditions. This suggests that the observed effect is not solely due to the selection of “healthier” patients for semaglutide therapy, although the authors emphasize that confounding factors cannot be completely ruled out.
It is also worth recalling that earlier randomized clinical trials have already demonstrated a beneficial effect of semaglutide on the risk of cardiovascular events. The new data expand this picture by suggesting a potential impact on hospitalization frequency, which may be relevant for treatment planning and cost assessments.
Experts stress that while the findings are promising, they require confirmation in randomized trials specifically designed to evaluate hospitalization outcomes. Until then, the data should be treated as a clinical signal rather than a basis for changing treatment guidelines.
